Tsuchiya Daijiro, Yamamoto Teiko, Kawasaki Ryo, Yamashita Hidetoshi
Department of Ophthalmology and Visual Science, Yamagata University Faculty of Medicine, Yamagata, Japan.
Retina. 2009 Jul-Aug;29(7):960-5. doi: 10.1097/IAE.0b013e3181a3b7c5.
PURPOSE: To describe the visual outcomes 2 years after photodynamic therapy in Japanese patients with age-related macular degeneration (AMD) with or without polypoidal choroidal vasculopathy (PCV) lesions. METHODS: Sixty-three eyes of 63 consecutive patients with AMD or AMD + PCV who underwent photodynamic therapy were included in this study. Fluorescein and indocyanine green angiography were performed to diagnose AMD and AMD + PCV. Change in mean visual acuity and recurrence of active lesion during the follow-up period up to 2 years were assessed. RESULTS: Patients with typical AMD maintained visual acuity for 2 years after photodynamic therapy. For patients with AMD + PCV, the visual acuity was maintained during the first year but started decreasing by 0.09 logarithm of the minimum angle of resolution units per 3 months (95% confidence intervals [CI], 0.06-0.14) after 1 year. Moreover, patients with AMD + PCV had 82% higher risk of a recurrence of active lesions for each increase in 3 months of follow-up time after 1 year; this suggested that the risk of recurrence had increased later in follow-up after 1 year. Recurrence of active PCV lesions and massive subretinal hemorrhages were the main reasons for the late worsening of visual acuity. CONCLUSION: The visual acuity after photodynamic therapy in AMD patients was maintained for 2 years after the initial treatment. Patients with AMD + PCV had stable visual outcome within 1 year but not after 1 year; there are risks of late recurrences and massive hemorrhages after 1 year in patients with AMD + PCV.
目的:描述接受光动力疗法的日本年龄相关性黄斑变性(AMD)患者(无论有无息肉样脉络膜血管病变(PCV))2年后的视力结果。 方法:本研究纳入了63例连续接受光动力疗法的AMD或AMD + PCV患者的63只眼。进行荧光素和吲哚菁绿血管造影以诊断AMD和AMD + PCV。评估了长达2年随访期内平均视力的变化和活动性病变的复发情况。 结果:典型AMD患者在光动力疗法后2年保持视力。对于AMD + PCV患者,视力在第一年保持稳定,但1年后开始以每3个月0.09最小分辨角对数单位下降(95%置信区间[CI],0.06 - 0.14)。此外,AMD + PCV患者在1年后每增加3个月的随访时间,活动性病变复发风险高82%;这表明随访1年后复发风险增加。活动性PCV病变复发和大量视网膜下出血是视力后期恶化的主要原因。 结论:AMD患者光动力疗法后的视力在初始治疗后2年保持稳定。AMD + PCV患者在1年内视力结果稳定,但1年后不稳定;AMD + PCV患者在1年后有后期复发和大量出血的风险。
Ophthalmic Surg Lasers Imaging. 2009
Am J Ophthalmol. 2006-10
Taiwan J Ophthalmol. 2019
Graefes Arch Clin Exp Ophthalmol. 2017-3
J Ophthalmic Vis Res. 2013-10